This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Monday's Health Winners & Losers

On Monday, earnings and a variety of news related to drug-eluting stents weren't enough to dislodge flat health indices.

Excluding items, Merck (MRK) earned 75 cents a share in the latest quarter, beating the consensus of 69 cents a share. Net income, including items, rose to $1.53 billion in the third quarter from $940.6 million in the same period a year ago.

Merck lifted its 2007 profit outlook, saying it should earn $3.08 to $3.14 a share, before items are counted. Analysts are looking for $3.07, according to Thomson Financial. Shares rose $1.37, or 2.6%, to $54.49.

On the other hand, Schering-Plough (SGP) earned 28 cents a share (excluding acquisition-related items and an upfront R&D payment), on revenue of $2.8 million. Analysts surveyed by Thomson Financial were expecting 30 cents a share on revenue of $2.87 million. Shares fell $4.25, or 13%, to $28.44.

Merck and Schering-Plough are both components of the Amex pharmaceutical index, which was down 2.48, or 0.7%, to 341.24.

Away from earnings, stents -- the mesh tubes sometimes frosted with antibiotic coating used to prop open clogged arteries -- have seen a decline in sales, but not in clinical trials or news.

First Medtronic (MDT) received the CE mark for the commercial sale of the Endeavor Resolute Drug-Eluting Coronary Stent in Europe and plans to launch the product outside the U.S. earlier than originally projected.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs